SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex ($CETX) is trending due to significant volatility and a large pre-market run, sparking discussions about potential short squeezes and future price targets among traders. The stock's high trading volume and low float are key points, with community members debating its potential for further gains and comparing it to other high-flying stocks. Some traders are expressing concerns about possible dilution, while others remain optimistic about a continued upward trend.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending due to a competing bid for WBD, creating uncertainty around its acquisition deal; the community is debating whether Netflix should increase its offer or walk away. Discussions include potential breakup fees, debt concerns, and the implications of a deal or no deal, with some suggesting political factors are influencing the outcome. Overall, investor sentiment seems mixed, with a focus on the potential impact on Netflix's financials and competitive positioning.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros Discovery is trending amid news of Paramount Skydance launching a hostile takeover bid, challenging the existing agreement with Netflix. The community is actively discussing the merits of each offer and the potential for a bidding war, alongside speculation about regulatory hurdles and the role of key figures like Trump and Ellison. Shareholders are weighing the potential benefits and risks associated with each deal as the media landscape faces further consolidation.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors eagerly await 48-week data for Pemvidutide, with speculation building around potential FDA feedback and breakthrough therapy designation. The community is buzzing about the possibility of the data confirming Pemvidutide's best-in-class potential for MASH treatment, particularly regarding statistically significant fibrosis improvement and weight loss. Discussions also involve potential buyout scenarios and comparisons to other companies in the MASH and weight loss space.

SAIHEAT Ltd. engages in the operation of cryptocurrency mining. It operates Bitcoin for its own account and provides full suite of services, purchase of mining machines, hosting service, and mining pool. The company was founded by Risheng Li on February 2, 2021, and is headquartered in Singapore.

SAIHEAT Ltd. - Ordinary Shares - Class A

SAIHEAT Ltd

SAIH is trending as traders discuss its potential as the next micro-float runner, drawing comparisons to recent high-flying stocks. The community highlights its small float and increasing volume, anticipating a possible short squeeze and significant upward movement. Positive sentiment is fueled by discussions of potential price targets and overnight holds.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending amidst a bidding war for Warner Bros. Discovery, with PSKY launching an all-cash tender offer. Community discussions revolve around whether WBD will accept PSKY's offer or a deal with Netflix, and potential regulatory hurdles. The involvement of sovereign wealth funds and political figures adds complexity to the situation.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community discusses its potential breakout and possible golden cross on the daily charts. Bullish sentiment is fueled by anticipation of a price surge, with some speculating about a run to higher price levels.  Conversations also highlight Litecoin's position as the 'digital silver' in the crypto space.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

ATMC is trending due to its recent merger approval with HCYC, sparking significant community interest. The stock's low float is fueling speculation of a potential short squeeze, reminiscent of other micro-float runners. Traders are actively discussing potential price targets and comparing it to similar plays like $SMX and $XCUR.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences ($WVE) is trending due to shareholder sales and discussions around a potential stock split following a recent offering, sparking debate about the company's financial strategy. The community is weighing the implications of the offering amidst existing cash reserves and upcoming milestones, while also considering the potential for a short squeeze given the stock's high volatility and significant trading volume. Discussions also highlight previous positive clinical trial results for their weight loss drug.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending after reporting positive Phase 2 trial results for its drug burixafor in multiple myeloma patients, showing high success in stem cell mobilization. The community is discussing the potential for secondary share offerings and comparing the stock's potential to previous runners. Some traders are focusing on the small float and speculating on a possible short squeeze, while others note the company's need for additional financing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL)

Stephens reaffirmed an "overweight" rating and set a $15.00 price target on shares of Candel Therapeutics in a research note on Monday...

Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat...

<ul class="summary-bullets"><li>Traders await the September Core PCE report, the Fed’s preferred inflation gauge. Market odds still overwhelmingly point to a rate cut next week.</li><li>Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.</li><li>Retail chatter is driving sharp moves in names like SMX, SoFi, Rubrik, and Praxis.</li></ul>U.S. stock futures are trading modestly higher in early trade on Friday, suggesting a positive start for Wall Street. It follows a mixed session yesterday and is primarily driven by stronger anticipation of a Federal Reserve rate cut at the upcoming December FOMC meeting.Among crucial economic data to monitor, the&nbsp;September Core PCE Price Index data releases today, which is considered the Fed's preferred inflation gauge.&nbsp;According to the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">&nbsp;CME FedWatch tool</a>, the market is now pricing in an 87% chance of an interest rate cut next Wednesday, down from 90% a day earlier.As of 2:45 a.m. ET on Thursday, the Nasdaq 100 futures and S&amp;P 500 futures were up 0.4% and 0.2%, while the Dow futures and the Russell 2000 futures were flattish with a positive bias. On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and that toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ early Thursday.&nbsp;Stocks On Trending Watchlist&nbsp;Netflix (NFLX) is reportedly winning the bidding war for a major WBD deal, outbidding Paramount (PSKY). Keep an eye on Warner Bros.Discovery (WBD) stock as well.&nbsp;Security Matters (SMX) is the top-trending stock on Stocktwits as retail chatter rises over a potential short squeeze. Retail sentiment is trending in ‘extremely high’ territory. In other news, the company approved key proposals and re-elected directors at its annual general meeting in Dublin.SoFi Technologies (SOFI) slipped&nbsp;over 6% in after-hours trading after an equity offering. It is looking to raise $1.5 billion in a share sale as it diversifies beyond lending into other products.Apple (AAPL)&nbsp;remains on retail radar on news of executive transitions focused on AI and ongoing regulatory reviews of its App Store rules in Europe.Rubrik (RBRK) saw a significant after-hours pop after a surprise profit and stronger guidance tied to AI demand.Samsara (IOT)&nbsp;has gained retail traction post a strong Q3 earnings print.&nbsp;Wells Fargo raised the firm's price target to $52 from $50 and keeps an Overweight rating on the shares, while JPMorgan raised the firm's price target to $48 from $46 and keeps a Neutral rating.Candel Therapeutics (CADL) is on retail radar on Friday. The company is scheduled to hold&nbsp;an R&amp;D event at 11:00 am ET to detail the BLA roadmap for prostate cancer drug CAN-2409.Praxis Precision Medicines (PRAX)&nbsp;is also inching higher on Stocktwit’s trending list after positive results from the EMBOLD relutrigine study. The company also&nbsp;confirmed it has an upcoming meeting with the FDA to discuss the results and the path forward for a New Drug Application (NDA).&nbsp;Other stocks to keep on the watchlist post their earnings release in after-hours are&nbsp;Domo (DOMO), HP Enterprise (HPE), SentinelOne (S), and DocuSign (DOCU).Key Catalysts To Watch Out ForOn the economic front, investors will be watching for data on inflation and consumer health ahead of the Federal Reserve's final policy meeting of the year.<ul><li>September Core PCE Price Index (10:00 am ET)</li><li>September Personal Income/Spending Data (10:00 am ET)</li><li>December Michigan Consumer Sentiment (10:00 am ET)</li><li>Consumer Credit Change (3:00 pm ET)</li></ul>And on the earnings front, investors will be watching for Victoria’s Secret ($VSCO) pre-market, among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.

Equity

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.


Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $24.00

Citigroup reduced their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday...

Candel Therapeutics (NASDAQ:CADL) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Candel Therapeutics (NASDAQ:CADL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat.com...

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer Trinity Capital Inc. Provides $130 Million in...

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Current Price	$5.45
Prev Close	$5.33
Open	$5.42
Dividend Yield	0.00%
50-Day Moving Average	$5.23
Beta	1.20
Avg. Volume	666,639.58
PE Ratio	-9.53

52-Week High	$14.60
52-Week Low	$4.25
Market Capitalization	$292.61M
EPS (Annual)	-$1.74
Price to Book	3.65
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADLCandel Therapeutics Inc